$BGNE Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in BeiGene, Ltd..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in BeiGene, Ltd.. Get notifications about new insider transactions in BeiGene, Ltd. for free.
Page: < prev 1 ... 2 3 4 5 6 7 8 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 28 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 148.88 | 2,190 | 326,045 | 4,938 | 7.1 K to 4.9 K (-30.72 %) |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 147.82 | 1,000 | 147,816 | 7,128 | 8.1 K to 7.1 K (-12.30 %) |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 146.70 | 2,575 | 377,749 | 8,128 | 10.7 K to 8.1 K (-24.06 %) |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 145.87 | 1,000 | 145,865 | 10,703 | 11.7 K to 10.7 K (-8.54 %) |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 144.75 | 800 | 115,798 | 11,703 | 12.5 K to 11.7 K (-6.40 %) |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 143.71 | 500 | 71,855 | 12,503 | 13 K to 12.5 K (-3.85 %) |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 146.41 | 800 | 117,127 | 13,003 | 13.8 K to 13 K (-5.80 %) |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 145.37 | 4,148 | 603,013 | 13,803 | 18 K to 13.8 K (-23.11 %) |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 144.62 | 3,475 | 502,545 | 17,951 | 21.4 K to 18 K (-16.22 %) |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 143.67 | 1,629 | 234,040 | 21,426 | 23.1 K to 21.4 K (-7.07 %) |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 142.35 | 800 | 113,880 | 23,055 | 23.9 K to 23.1 K (-3.35 %) |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 141.12 | 200 | 28,224 | 23,855 | 24.1 K to 23.9 K (-0.83 %) |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 139.57 | 200 | 27,914 | 24,055 | 24.3 K to 24.1 K (-0.82 %) |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 141.98 | 805 | 114,293 | 24,255 | 25.1 K to 24.3 K (-3.21 %) |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 140.97 | 1,100 | 155,070 | 25,060 | 26.2 K to 25.1 K (-4.20 %) |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 140.05 | 2,605 | 364,821 | 26,160 | 28.8 K to 26.2 K (-9.06 %) |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 138.98 | 968 | 134,534 | 28,765 | 29.7 K to 28.8 K (-3.26 %) |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 137.98 | 1,400 | 193,174 | 29,733 | 31.1 K to 29.7 K (-4.50 %) |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 136.77 | 2,000 | 273,543 | 31,133 | 33.1 K to 31.1 K (-6.04 %) |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 134.98 | 200 | 26,995 | 33,133 | 33.3 K to 33.1 K (-0.60 %) |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Option Exercise | M | 2.27 | 39,000 | 88,530 | 1,328,500 | |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 139.58 | 3,000 | 418,750 | 0 | 3 K to 0 (-100.00 %) |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Buy | M | 29.49 | 3,000 | 88,470 | 3,000 | 0 to 3 K |
| Nov 28 2018 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Gift | G | 0.00 | 89,999 | 0 | 7,773,608 | 7.9 M to 7.8 M (-1.14 %) |
| Nov 21 2018 | BGNE | BeiGene, Ltd. | Glazer Donald W. | Director | Gift | G | 0.00 | 3,138 | 0 | 4,127,526 | 4.1 M to 4.1 M (-0.08 %) |
| Nov 21 2018 | BGNE | BeiGene, Ltd. | Glazer Donald W. | Director | Gift | G | 0.00 | 3,138 | 0 | 4,130,664 | 4.1 M to 4.1 M (-0.08 %) |
| Nov 21 2018 | BGNE | BeiGene, Ltd. | Glazer Donald W. | Director | Gift | G | 0.00 | 3,138 | 0 | 4,133,802 | 4.1 M to 4.1 M (-0.08 %) |
| Nov 21 2018 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Sell | S | 126.53 | 600 | 75,918 | 0 | 600 to 0 (-100.00 %) |
| Nov 21 2018 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Sell | S | 125.56 | 850 | 106,728 | 600 | 1.5 K to 600 (-58.62 %) |
| Nov 21 2018 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Sell | S | 124.55 | 1,173 | 146,098 | 1,450 | 2.6 K to 1.5 K (-44.72 %) |
| Nov 21 2018 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Sell | S | 123.68 | 1,277 | 157,945 | 2,623 | 3.9 K to 2.6 K (-32.74 %) |
| Nov 21 2018 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Sell | S | 122.55 | 1,100 | 134,801 | 3,900 | 5 K to 3.9 K (-22.00 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Option Exercise | M | 2.24 | 156,871 | 351,391 | 1,080,000 | |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Option Exercise | M | 2.24 | 171,886 | 385,025 | 1,236,871 | |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Option Exercise | M | 2.24 | 191,243 | 428,384 | 1,408,757 | |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 121.56 | 100 | 12,156 | 0 | 100 to 0 (-100.00 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 117.61 | 109 | 12,820 | 100 | 209 to 100 (-52.15 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 116.56 | 500 | 58,281 | 209 | 709 to 209 (-70.52 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 114.96 | 700 | 80,472 | 709 | 1.4 K to 709 (-49.68 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 113.92 | 1,173 | 133,630 | 1,409 | 2.6 K to 1.4 K (-45.43 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 113.03 | 2,527 | 285,632 | 2,582 | 5.1 K to 2.6 K (-49.46 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 112.18 | 4,000 | 448,720 | 5,109 | 9.1 K to 5.1 K (-43.91 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 111.10 | 2,958 | 328,638 | 9,109 | 12.1 K to 9.1 K (-24.51 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Buy | M | 29.10 | 12,067 | 351,150 | 12,067 | 0 to 12.1 K |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 125.97 | 100 | 12,597 | 0 | 100 to 0 (-100.00 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 123.75 | 322 | 39,847 | 100 | 422 to 100 (-76.30 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 122.55 | 2,046 | 250,733 | 422 | 2.5 K to 422 (-82.90 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 121.71 | 2,898 | 352,704 | 2,468 | 5.4 K to 2.5 K (-54.01 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 120.63 | 2,100 | 253,325 | 5,366 | 7.5 K to 5.4 K (-28.13 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 119.27 | 1,725 | 205,740 | 7,466 | 9.2 K to 7.5 K (-18.77 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 118.64 | 4,031 | 478,218 | 9,191 | 13.2 K to 9.2 K (-30.49 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Buy | M | 29.10 | 13,222 | 384,760 | 13,222 | 0 to 13.2 K |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 127.61 | 200 | 25,522 | 0 | 200 to 0 (-100.00 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 126.72 | 7,673 | 972,320 | 200 | 7.9 K to 200 (-97.46 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 126.08 | 3,949 | 497,879 | 7,873 | 11.8 K to 7.9 K (-33.40 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 124.48 | 2,423 | 301,605 | 11,822 | 14.2 K to 11.8 K (-17.01 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 122.86 | 466 | 57,251 | 14,245 | 14.7 K to 14.2 K (-3.17 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Buy | M | 29.10 | 14,711 | 428,090 | 14,711 | 0 to 14.7 K |
| Sep 05 2018 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 174.60 | 2,911 | 508,247 | 0 | 2.9 K to 0 (-100.00 %) |
| Aug 31 2018 | BGNE | BeiGene, Ltd. | Glazer Donald W. | Director | Sell | S | 179.00 | 1,000 | 179,000 | 13,384 | 14.4 K to 13.4 K (-6.95 %) |
| Aug 31 2018 | BGNE | BeiGene, Ltd. | Glazer Donald W. | Director | Sell | S | 179.00 | 1,000 | 179,000 | 14,384 | 15.4 K to 14.4 K (-6.50 %) |
| Aug 24 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 170.46 | 961 | 163,815 | 0 | 961 to 0 (-100.00 %) |
| Aug 24 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 169.75 | 1,400 | 237,656 | 961 | 2.4 K to 961 (-59.30 %) |
| Aug 24 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 168.94 | 2,300 | 388,565 | 2,361 | 4.7 K to 2.4 K (-49.35 %) |
| Aug 24 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 167.54 | 1,108 | 185,630 | 4,661 | 5.8 K to 4.7 K (-19.21 %) |
| Aug 15 2018 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Sell | S | 164.11 | 549 | 90,096 | 0 | 549 to 0 (-100.00 %) |
| Aug 15 2018 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Sell | S | 159.21 | 700 | 111,450 | 549 | 1.2 K to 549 (-56.04 %) |
| Aug 15 2018 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Sell | S | 157.29 | 2,200 | 346,044 | 1,249 | 3.4 K to 1.2 K (-63.79 %) |
| Aug 06 2018 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | P | 108.00 | 5,231,900 | 565,045,200 | 5,250,491 | 18.6 K to 5.3 M (+28,142.11 %) |
| Aug 06 2018 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | P | 108.00 | 582,200 | 62,877,600 | 600,791 | 18.6 K to 600.8 K (+3,131.62 %) |
| Jul 17 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 164.12 | 2,550 | 418,497 | 0 | 2.6 K to 0 (-100.00 %) |
| Jun 28 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Option Exercise | A | 12.34 | 1,310,088 | 16,166,486 | 1,310,088 | |
| Jun 28 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Grant | A | 0.00 | 188,266 | 0 | 17,453,322 | 17.3 M to 17.5 M (+1.09 %) |
| Jun 28 2018 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Option Exercise | A | 12.34 | 364,208 | 4,494,327 | 364,208 | |
| Jun 28 2018 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Grant | A | 0.00 | 52,338 | 0 | 52,338 | 0 to 52.3 K |
| Jun 28 2018 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Option Exercise | A | 12.34 | 310,180 | 3,827,621 | 310,180 | |
| Jun 28 2018 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Grant | A | 0.00 | 44,564 | 0 | 309,464 | 264.9 K to 309.5 K (+16.82 %) |
| Jun 28 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Option Exercise | A | 12.34 | 310,180 | 3,827,621 | 310,180 | |
| Jun 28 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Grant | A | 0.00 | 44,564 | 0 | 269,566 | 225 K to 269.6 K (+19.81 %) |
| Jun 28 2018 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Option Exercise | A | 12.34 | 655,044 | 8,083,243 | 655,044 | |
| Jun 28 2018 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Grant | A | 0.00 | 94,133 | 0 | 7,973,444 | 7.9 M to 8 M (+1.19 %) |
| Jun 28 2018 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Gift | G | 0.00 | 5,000,000 | 0 | 7,879,311 | 12.9 M to 7.9 M (-38.82 %) |
| Jun 08 2018 | BGNE | BeiGene, Ltd. | Yi Qingqing | Director | Option Exercise | A | 16.15 | 17,442 | 281,688 | 17,442 | |
| Jun 08 2018 | BGNE | BeiGene, Ltd. | Yi Qingqing | Director | Grant | A | 0.00 | 9,290 | 0 | 9,290 | 0 to 9.3 K |
| Jun 08 2018 | BGNE | BeiGene, Ltd. | Glazer Donald W. | Director | Option Exercise | A | 16.15 | 17,442 | 281,688 | 17,442 | |
| Jun 08 2018 | BGNE | BeiGene, Ltd. | Glazer Donald W. | Director | Grant | A | 0.00 | 9,290 | 0 | 4,336,932 | 4.3 M to 4.3 M (+0.21 %) |
| Jun 08 2018 | BGNE | BeiGene, Ltd. | Glazer Donald W. | Director | Gift | G | 0.00 | 199,992 | 0 | 4,327,642 | 4.5 M to 4.3 M (-4.42 %) |
| Jun 08 2018 | BGNE | BeiGene, Ltd. | Glazer Donald W. | Director | Gift | G | 0.00 | 10,873 | 0 | 4,527,634 | 4.5 M to 4.5 M (-0.24 %) |
| Jun 08 2018 | BGNE | BeiGene, Ltd. | Chen Timothy Yung-Cheng | Director | Option Exercise | A | 16.15 | 17,442 | 281,688 | 17,442 | |
| Jun 08 2018 | BGNE | BeiGene, Ltd. | Chen Timothy Yung-Cheng | Director | Grant | A | 0.00 | 9,290 | 0 | 9,290 | 0 to 9.3 K |
| Jun 08 2018 | BGNE | BeiGene, Ltd. | Malley Thomas | Director | Option Exercise | A | 16.15 | 17,442 | 281,688 | 17,442 | |
| Jun 08 2018 | BGNE | BeiGene, Ltd. | Malley Thomas | Director | Grant | A | 0.00 | 9,290 | 0 | 9,290 | 0 to 9.3 K |
| Jun 08 2018 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 16.15 | 34,884 | 563,377 | 34,884 | |
| Jun 08 2018 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 18,580 | 0 | 73,180,602 | 73.2 M to 73.2 M (+0.03 %) |
| Jun 08 2018 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 18,580 | 0 | 6,551,715 | 6.5 M to 6.6 M (+0.28 %) |
| May 02 2018 | BGNE | BeiGene, Ltd. | Wu Xiaobin | President & GM Chin ... | Option Exercise | A | 13.05 | 766,599 | 10,004,117 | 766,599 | |
| May 02 2018 | BGNE | BeiGene, Ltd. | Wu Xiaobin | President & GM Chin ... | Grant | A | 0.00 | 1,149,899 | 0 | 1,149,899 | 0 to 1.1 M |
| May 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Option Exercise | A | 13.05 | 996,810 | 13,008,371 | 996,810 | |
| May 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Grant | A | 0.00 | 574,938 | 0 | 17,265,056 | 16.7 M to 17.3 M (+3.44 %) |
| Apr 04 2018 | BGNE | BeiGene, Ltd. | su Jingshyh S | Director | Option Exercise | A | 12.72 | 63,290 | 805,049 | 63,290 | |
| Mar 20 2018 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Option Exercise | M | 0.50 | 313,664 | 156,832 | 4,445,000 | |
| Mar 20 2018 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Option Exercise | M | 0.50 | 141,336 | 70,668 | 4,758,664 | |
| Mar 20 2018 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 164.36 | 900 | 147,923 | 0 | 900 to 0 (-100.00 %) |
| Mar 20 2018 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 163.48 | 4,636 | 757,902 | 900 | 5.5 K to 900 (-83.74 %) |
| Mar 20 2018 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 162.79 | 5,133 | 835,583 | 5,536 | 10.7 K to 5.5 K (-48.11 %) |
| Mar 20 2018 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 161.62 | 3,141 | 507,661 | 10,669 | 13.8 K to 10.7 K (-22.74 %) |
| Mar 20 2018 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 160.60 | 9,618 | 1,544,652 | 13,810 | 23.4 K to 13.8 K (-41.05 %) |
| Mar 20 2018 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 159.62 | 5,200 | 830,042 | 23,428 | 28.6 K to 23.4 K (-18.16 %) |
| Mar 20 2018 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 158.45 | 500 | 79,224 | 28,628 | 29.1 K to 28.6 K (-1.72 %) |
| Mar 20 2018 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Buy | M | 6.50 | 24,128 | 156,832 | 29,128 | 5 K to 29.1 K (+482.56 %) |
| Mar 20 2018 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 157.98 | 400 | 63,191 | 5,000 | 5.4 K to 5 K (-7.41 %) |
| Mar 20 2018 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 157.41 | 7,264 | 1,143,430 | 5,400 | 12.7 K to 5.4 K (-57.36 %) |
| Mar 20 2018 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 156.75 | 2,208 | 346,095 | 12,664 | 14.9 K to 12.7 K (-14.85 %) |
| Mar 20 2018 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 154.95 | 1,000 | 154,950 | 14,872 | 15.9 K to 14.9 K (-6.30 %) |
| Mar 20 2018 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Buy | M | 6.50 | 10,872 | 70,668 | 15,872 | 5 K to 15.9 K (+217.44 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 150.57 | 6,584 | 991,321 | 0 | 6.6 K to 0 (-100.00 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 149.75 | 9,032 | 1,352,531 | 6,584 | 15.6 K to 6.6 K (-57.84 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 148.61 | 2,800 | 416,117 | 15,616 | 18.4 K to 15.6 K (-15.20 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 147.31 | 700 | 103,114 | 18,416 | 19.1 K to 18.4 K (-3.66 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 146.25 | 200 | 29,249 | 19,116 | 19.3 K to 19.1 K (-1.04 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 145.32 | 600 | 87,189 | 19,316 | 19.9 K to 19.3 K (-3.01 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 143.64 | 1,546 | 222,067 | 19,916 | 21.5 K to 19.9 K (-7.20 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 142.73 | 2,600 | 371,084 | 21,462 | 24.1 K to 21.5 K (-10.81 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 141.62 | 1,300 | 184,111 | 24,062 | 25.4 K to 24.1 K (-5.13 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 145.00 | 2,656 | 385,116 | 25,362 | 28 K to 25.4 K (-9.48 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 144.26 | 14,354 | 2,070,747 | 28,018 | 42.4 K to 28 K (-33.88 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 143.31 | 10,303 | 1,476,472 | 42,372 | 52.7 K to 42.4 K (-19.56 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 142.20 | 4,787 | 680,699 | 52,675 | 57.5 K to 52.7 K (-8.33 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 141.22 | 3,350 | 473,094 | 57,462 | 60.8 K to 57.5 K (-5.51 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 140.38 | 1,250 | 175,470 | 60,812 | 62.1 K to 60.8 K (-2.01 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 139.08 | 2,600 | 361,606 | 62,062 | 64.7 K to 62.1 K (-4.02 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 152.00 | 200 | 30,400 | 64,662 | 64.9 K to 64.7 K (-0.31 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 150.98 | 100 | 15,098 | 64,862 | 65 K to 64.9 K (-0.15 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 149.68 | 3,117 | 466,558 | 64,962 | 68.1 K to 65 K (-4.58 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 149.13 | 5,342 | 796,675 | 68,079 | 73.4 K to 68.1 K (-7.28 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 147.84 | 2,302 | 340,320 | 73,421 | 75.7 K to 73.4 K (-3.04 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 146.96 | 8,449 | 1,241,625 | 75,723 | 84.2 K to 75.7 K (-10.04 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 146.02 | 4,607 | 672,722 | 84,172 | 88.8 K to 84.2 K (-5.19 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 144.86 | 5,104 | 739,357 | 88,779 | 93.9 K to 88.8 K (-5.44 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Sell | S | 143.48 | 5,117 | 734,187 | 93,883 | 99 K to 93.9 K (-5.17 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | Li Ji | EVP and Gl. Head of ... | Option Exercise | M | 2.05 | 130,000 | 266,500 | 2,246,000 | |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | Li Ji | EVP and Gl. Head of ... | Sell | S | 149.49 | 2,400 | 358,769 | 0 | 2.4 K to 0 (-100.00 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | Li Ji | EVP and Gl. Head of ... | Sell | S | 148.66 | 1,551 | 230,576 | 2,400 | 4 K to 2.4 K (-39.26 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | Li Ji | EVP and Gl. Head of ... | Sell | S | 146.92 | 1,800 | 264,448 | 3,951 | 5.8 K to 4 K (-31.30 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | Li Ji | EVP and Gl. Head of ... | Sell | S | 145.97 | 1,400 | 204,351 | 5,751 | 7.2 K to 5.8 K (-19.58 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | Li Ji | EVP and Gl. Head of ... | Sell | S | 144.78 | 1,100 | 159,254 | 7,151 | 8.3 K to 7.2 K (-13.33 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | Li Ji | EVP and Gl. Head of ... | Sell | S | 143.72 | 1,749 | 251,361 | 8,251 | 10 K to 8.3 K (-17.49 %) |
| Mar 02 2018 | BGNE | BeiGene, Ltd. | Li Ji | EVP and Gl. Head of ... | Buy | M | 26.65 | 10,000 | 266,500 | 10,000 | 0 to 10 K |
| Jan 22 2018 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | P | 101.00 | 1,645,148 | 166,159,948 | 5,121,404 | 3.5 M to 5.1 M (+47.33 %) |
| Jan 22 2018 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | P | 101.00 | 335,050 | 33,840,050 | 708,025 | 373 K to 708 K (+89.83 %) |